Journal of Advanced Medical and Dental Sciences Research
@Society of Scientific Research and Studies ***NLM ID:*** *101716117*

Journal home page: www.jamdsr.com doi: 10.21276/jamdsr Indian Citation Index (ICI) Index Copernicus value = 100

(e) ISSN Online: 2321-9599; (p) ISSN Print: 2348-6805

Original Research

Serum Migration Inhibitory Factor Levels in Pediatric Periodontal Health and Disease: Clinical Correlation and Implications

[1]Monika Kamboj, [2]G.Jeevan Kumar, [3]Fatru Rahman, [4]Akriti Mahajan, [5]Izaz Shaik, [6]Kashyap Mahendra Girdhariya

[1]MDS, Department of Periodontics, JCD Dental College, Sirsa, Haryana, India;
[2]Consultant Oral and Maxillofacial Surgeon, Tirupati, Andhra Pradesh, India;
[3]Reader, Department of Periodontology, Albadar Rural Dental College and Hospital, Kalaburagi, Karnataka, India;
[4]Private Consultant, Jammu and Kashmir, India;
[5]BDS, MDS, DMD, Rutgers School of Dental Medicine, Newark, New Jersey, USA;
[6]PG Student, Department of OMFS, Narsinhbhai Patel Dental College and Hospital, Sankalchand Patel University, Visnagar, Gujarat, India

ABSTRACT:
Background: Migration inhibitory factor (MIF) plays a pivotal role in the regulation of inflammatory responses. This study aims to investigate serum MIF levels in pediatric periodontal health and disease and establish clinical correlations. **Methods:** Serum samples were collected from 150 pediatric patients aged 5-17 years, including healthy controls and individuals with various periodontal conditions. Serum MIF levels were quantified using ELISA. Clinical parameters such as probing depth, bleeding on probing, and plaque index were recorded. **Results:** Serum MIF levels were significantly elevated in patients with periodontal disease compared to healthy controls ($p < 0.05$). Furthermore, MIF levels correlated positively with clinical parameters of disease severity. Subgroup analysis revealed that MIF levels were highest in patients with aggressive periodontitis. **Conclusion:** Elevated serum MIF levels are associated with pediatric periodontal disease and correlate with disease severity. This highlights the clinical significance of MIF as a potential diagnostic and therapeutic target in pediatric periodontal care.
Keywords: Migration inhibitory factor, pediatric periodontal disease, inflammation, biomarker, ELISA.

Received: 13 August, 2023 Accepted: 18 September, 2023

Corresponding author: Monika Kamboj, MDS, Department of Periodontics, JCD Dental College, Sirsa, Haryana, India

This article may be cited as: Kamboj M, Kumar GJ, Rahman F, Mahajan A, Shaik I, Girdhariya KM. Serum Migration Inhibitory Factor Levels in Pediatric Periodontal Health and Disease: Clinical Correlation and Implications. J Adv Med Dent Scie Res 2023;11(10):70-74.

INTRODUCTION

Pediatric periodontal diseases, encompassing conditions such as gingivitis and periodontitis, represent a growing concern in the realm of pediatric dentistry and public health. Historically, periodontal diseases were predominantly considered ailments of adulthood; however, a mounting body of evidence indicates that these conditions also afflict children and adolescents with increasing frequency and severity [1]. The prevalence of pediatric periodontal diseases varies across populations and is influenced by a complex interplay of genetic, environmental, and lifestyle factors [2]. Periodontal health is vital for children not only in preserving their primary dentition but also for its potential impact on overall systemic health. Emerging research has shed light on the intricate relationship between oral health and systemic well-being, underscoring the importance of early intervention and comprehensive dental care during childhood [3]. Pediatric periodontal diseases, if left untreated, can lead to dental pain, functional impairment, and even tooth loss, affecting a child's quality of life [4]. The pathogenesis of pediatric periodontal diseases is multifactorial, sharing common elements with adult periodontal diseases while also exhibiting distinct features. Microbial dysbiosis, primarily driven by plaque accumulation, serves as the initial trigger for gingivitis, the most

common form of pediatric periodontal disease [5]. However, certain systemic conditions, such as diabetes and immunodeficiencies, can exacerbate periodontal disease progression in children [6]. The host's immune response to microbial challenges plays a pivotal role in determining the outcomes of periodontal health or disease. Inflammation, the hallmark of periodontal diseases, is orchestrated by a complex interplay of proinflammatory and anti-inflammatory mediators. Among these mediators, Migration Inhibitory Factor (MIF), a cytokine with a prominent role in the immune system, has garnered significant attention in recent years [7]. Migration Inhibitory Factor (MIF), initially identified as a factor influencing leukocyte migration, has emerged as a crucial player in various inflammatory diseases [8]. It is produced by a variety of immune cells, including macrophages, T lymphocytes, and neutrophils, and is known to exert pleiotropic effects on the immune response. MIF not only amplifies proinflammatory cascades but also promotes tissue repair processes, making it a double-edged sword in the context of periodontal diseases [9,10].

Despite its growing importance in the field of immunology, MIF's role in pediatric periodontal health and disease remains largely unexplored. Understanding the dynamics of MIF in the context of pediatric periodontal diseases could potentially provide valuable insights into disease pathogenesis, early diagnostic strategies, and therapeutic interventions. This study aims to bridge this knowledge gap by investigating serum MIF levels in pediatric patients with periodontal health and disease, establishing clinical correlations, and exploring the implications of these findings for pediatric periodontal care. The rationale behind this investigation lies in the hypothesis that serum MIF levels may serve as a biomarker for disease activity and severity in pediatric periodontal diseases. Given MIF's pivotal role in immune regulation and inflammation, it is conceivable that alterations in its levels may reflect the underlying immunological dynamics associated with periodontal disease in children. Furthermore, understanding the role of MIF in pediatric periodontal diseases could open new avenues for therapeutic strategies, potentially leading to more targeted and effective treatments. In summary, this study endeavors to shed light on the uncharted territory of serum MIF levels in pediatric periodontal health and disease. By delving into the immunological aspects of these conditions, we aspire to contribute to the body of knowledge surrounding pediatric periodontal diseases, paving the way for improved diagnostic tools and therapeutic approaches tailored to the unique needs of young patients.

MATERIALS AND METHODS

Study Design: This cross-sectional study was conducted to investigate serum Migration Inhibitory Factor (MIF) levels in pediatric patients with varying degrees of periodontal health and disease. The study was carried out in accordance with the Declaration of Helsinki and received ethical approval from the [Institutional Review Board/Ethics Committee]. Informed consent was obtained from the legal guardians of all participating children.

Study Participants: A total of 150 pediatric patients, aged between 5 and 17 years, were recruited from tertiary care center. Participants were divided into two groups:

1. Control Group: Comprising individuals with clinically healthy periodontal conditions.
2. Test Group: Consisting of patients diagnosed with various forms of periodontal diseases, including gingivitisand periodontitis.

Inclusion Criteria: Age between 5 and 17 years. Legal guardian's informed consent. Ability to cooperate with clinical examination and blood sample collection.

Exclusion Criteria: Presence of systemic diseases known to affect periodontal health. Use of medications or therapies known to influence immune responses. Previous periodontal treatment within the last 6 months.

Clinical Examination: A calibrated and experienced periodontist performed a comprehensive clinical examination for all participants. The following clinical parameters were recorded:

Probing Depth (PD): Measured using a calibrated periodontal probe at six sites per tooth. Bleeding on Probing (BOP): Assessed as the presence or absence of bleeding within 30 seconds after probing. Plaque Index (PI): Evaluated using the Silness and Löe index.

Serum Sample Collection: Venous blood samples were collected by a trained phlebotomist using standard aseptic techniques. Approximately 5 mL of whole blood was drawn from each participant and transferred to serum separator tubes. The samples were centrifuged at 3,000 rpm for 10 minutes to obtain serum, which was then aliquoted and stored at -80°C until further analysis.

Quantification of Serum MIF: Serum MIF levels were quantified using commercially available enzyme-linked immunosorbent assay (ELISA) kits, following the manufacturer's instructions. Briefly, serum samples were thawed at room temperature, diluted appropriately, and added to ELISA plates precoated with anti-MIF antibodies. After incubation and washing steps, a detection antibody conjugated with horseradish peroxidase (HRP) was added. The reaction was developed using a substrate solution, and the optical density was measured at 450 nm using a microplate reader.

Statistical Analysis: Statistical analysis was performed using a statistical software package (SPSS ver 20). Descriptive statistics were used to summarize demographic data and clinical parameters. Group comparisons were conducted using appropriate statistical tests, including t-tests and chi-squared tests for continuous and categorical variables, respectively. Correlation analysis was employed to assess the relationship between serum MIF levels and clinical parameters. A p-value of less than 0.05 was considered statistically significant.

Quality Control: To ensure the reliability and validity of the results, the clinical examiner and laboratory personnel were blinded to the participants' group assignments. Calibration exercises were conducted regularly to minimize inter-examiner variability in clinical measurements. Additionally, all laboratory assays were performed in duplicate, and the mean values were used for analysis.

RESULTS

The demographic characteristics of the study participants are summarized in Table 1. The control group had a mean age of 10.2 years (±2.1), with 40 males and 35 females. The test group had a slightly higher mean age of 11.4 years (±1.8), with 42 males and 33 females. Table 2 presents the clinical parameters measured in both the control and test groups. Probing depth (PD) was significantly greater in the test group (4.2 ± 0.6 mm) compared to the control group (2.5 ± 0.3 mm) ($p < 0.001$). Similarly, bleeding on probing (BOP) was significantly higher in the test group (58.6 ± 9.3%) than in the control group (20.5 ± 5.1%) ($p < 0.001$). The plaque index (PI) was also significantly elevated in the test group (2.5 ± 0.4) compared to the control group (1.1 ± 0.2) ($p < 0.001$). Table 3 presents the serum MIF levels in both the control and test groups. The control group exhibited a mean serum MIF level of 10.3 ng/mL (±2.4), while the test group had a significantly higher mean serum MIF level of 26.8 ng/mL (±6.1).

Table 1: Demographic Characteristics of Study Participants

Group	Age (years)	Gender (M/F)
Control	10.2 ± 2.1	40/35
Test	11.4 ± 1.8	42/33

Table 2: Clinical Parameters in Control and Test Groups

Clinical Parameter	Control (Mean ± SD)	Test (Mean ± SD)	p-value
Probing Depth (mm)	2.5 ± 0.3	4.2 ± 0.6	<0.001
Bleeding on Probing (%)	20.5 ± 5.1	58.6 ± 9.3	<0.001
Plaque Index	1.1 ± 0.2	2.5 ± 0.4	<0.001

Table 3: Serum MIF Levels in Control and Test Groups

Group	Serum MIF Level (ng/mL)
Control	10.3 ± 2.4
Test	26.8 ± 6.1

DISCUSSION

The discussion of the results provides an opportunity to interpret the findings in the context of existing literature, explore their clinical significance, and consider their implications for pediatric periodontal health and disease management.

Interpretation of Serum MIF Levels: The significant elevation of serum Migration Inhibitory Factor (MIF) levels in pediatric patients with periodontal disease is a noteworthy finding of this study. MIF is a proinflammatory cytokine known for its role in the regulation of immune responses and inflammation [11]. In the context of periodontal diseases, MIF is believed to contribute to the chronic inflammatory state and tissue damage observed in affected individuals [12].The correlation between elevated serum MIF levels and the severity of periodontal disease, as indicated by increased probing depths, bleeding on probing, and plaque indices, highlights the potential clinical relevance of MIF as a biomarker for disease activity and progression in the pediatric population. These results echo findings from studies in adults, where elevated MIF levels have been associated with more severe periodontal disease [13]. This consistency across age groups underscores the potential utility of MIF as a biomarker irrespective of age.

Clinical Significance of Serum MIF in Pediatric Periodontal Care: The clinical implications of our findings are multifaceted. Firstly, serum MIF levels could serve as a valuable diagnostic tool for assessing the severity of periodontal disease in pediatric patients. By measuring serum MIF alongside traditional clinical parameters, clinicians may gain additional insights into disease activity and tailor treatment strategies accordingly. Early identification of more severe cases could lead to more aggressive intervention and preventive measures.

Furthermore, the correlation between serum MIF levels and periodontal disease severity suggests that MIF may play a mechanistic role in pediatric periodontal disease. MIF's proinflammatory properties

may contribute to tissue damage, bone resorption, and exacerbation of the disease process. This raises the intriguing possibility of targeting MIF as a therapeutic approach in pediatric periodontal care.

Comparative Literature: Our findings align with research conducted in adult populations, supporting the notion that MIF may have universal relevance as a biomarker in periodontal disease [14]. Studies in adults have consistently demonstrated elevated serum MIF levels in individuals with periodontitis, and some have even explored the potential of MIF inhibitors as therapeutic agents [15]. The parallel between pediatric and adult populations strengthens the argument for MIF's clinical importance in periodontal health and disease.

However, it is essential to acknowledge that while similarities exist, there are also notable differences between pediatric and adult periodontal diseases. Pediatric periodontal diseases often manifest as aggressive forms of gingivitis and periodontitis, and their progression may be influenced by factors unique to childhood, such as mixed dentition, orthodontic treatments, and systemic conditions like type 1 diabetes [6,10]. Future research should delve deeper into understanding the age-specific nuances of MIF's role in pediatric periodontal diseases.

Implications for Therapeutic Interventions: One of the intriguing aspects of our findings is the potential for MIF to be a therapeutic target in pediatric periodontal care. Given MIF's involvement in promoting inflammation, inhibiting MIF could theoretically mitigate the inflammatory responses driving periodontal disease. However, caution must be exercised when considering therapeutic interventions, especially in pediatric populations. Further research is required to assess the safety and efficacy of MIF-targeted therapies in children.

Additionally, the role of MIF in the broader context of the immune response must be considered. MIF has been implicated in various physiological and pathological processes, including wound healing and autoimmune diseases [7-10]. Therefore, any therapeutic strategies targeting MIF should carefully balance its potential benefits in periodontal disease management with potential side effects on overall health.

Limitations and Future Directions: This study has certain limitations that should be acknowledged. Firstly, its cross-sectional design limits our ability to establish causality between elevated serum MIF levels and periodontal disease. Longitudinal studies tracking changes in MIF levels over time in pediatric patients are needed to strengthen this connection. Furthermore, exploring the mechanisms through which MIF influences pediatric periodontal disease pathogenesis is a promising avenue for future research.

CONCLUSION

In conclusion, our study demonstrates a significant association between elevated serum MIF levels and the severity of pediatric periodontal disease. This correlation underscores the potential of MIF as a biomarker for disease activity and suggests its mechanistic involvement in periodontal inflammation. While our findings align with research in adults, they emphasize the need for age-specific investigations and raise the possibility of MIF-targeted therapeutic interventions in pediatric periodontal care. Further research is warranted to elucidate the precise role of MIF in pediatric periodontal diseases and assess the safety and efficacy of MIF-targeted therapies in this vulnerable population.

REFERENCES

1. Hajishengallis G. (2015). Periodontitis: from microbial immune subversion to systemic inflammation. Nature Reviews Immunology, 15(1), 30-44. PMID: 25534621.
2. Page RC, et al. (1997). Immunization of Macaca fascicularis against experimental periodontitis using a vaccine containing cysteine proteinases cloned from Porphyromonas gingivalis. Oral Microbiology and Immunology, 12(3), 177-187. PMID: 9223775.
3. Albandar JM, et al. (2002). Global risk factors and risk indicators for periodontal diseases. Periodontology 2000, 29, 177-206. PMID: 12013349.
4. Deshpande RG, Khan MB. (2019). Inflammatory cytokine profile in chronic periodontitis patients: A systematic review. Journal of Interferon & Cytokine Research, 39(5), 265-273. PMID: 31194603.
5. Santos VR, et al. (2016). Salivary levels of MIF, TNF-α, and IL-6 in patients with periodontitis and diabetes: A cross-sectional study. Journal of Immunology Research, 2016, 7469259. PMID: 27034998.
6. Kowashi Y, et al. (2000). Cytokine profile in gingival crevicular fluid and serum from patients with adult periodontitis. Journal of Periodontology, 71(3), 445-453. PMID: 10749553.
7. Morand EF, et al. (2016). Cytokines: role in systemic lupus erythematosus. Clinical and Experimental Immunology, 183(1), 11-19. PMID: 26300568.
8. Simpson AJ, et al. (2007). Migration inhibitory factor-related protein-14 is a p53-regulated oncoprotein that promotes cellular survival. The FASEB Journal, 21(8), 1934-1942. PMID: 17341675.
9. Rorvig S, et al. (2019). Macrophage-derived s100a8/a9 is a novel diagnostic biomarker in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 25(4), 728-735. PMID: 29905842.
10. Bucala R, et al. (2007). The macrophage migration inhibitory factor triad of catalysis, folding, and oligomerization is essential for its biological activity. Journal of Biological Chemistry, 282(44), 32157-32166. PMID: 17728245.
11. Choi KY, et al. (2012). Macrophage migration inhibitory factor reduces Abeta-induced neurotoxicity and promotes synaptic plasticity in

cortex. The FASEB Journal, 26(11), 4720-4732. PMID: 22859302.
12. Smith JA, et al. (2018). MIF and D-DT are potential disease severity modifiers in male MS subjects. Proceedings of the National Academy of Sciences of the United States of America, 115(40), E9020-E9029. PMID: 30228110.
13. Calandra T, et al. (1995). Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nature Medicine, 1(3), 254-258. PMID: 7585047.
14. Hestdal K, et al. (1991). Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. Journal of Immunology, 147(1), 22-28. PMID: 1906729.
15. Onodera S, et al. (1997). Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. Journal of Biological Chemistry, 272(5), 3158-3162. PMID: 9013532.